Tumor suppressor PTEN in breast cancer: Heterozygosity, mutations and protein expression

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1387-1400

  Kechagioglou, Petros ^a   Papi, Rigini M ^a   Provatopoulou, Xeni ^b   Kalogera, Eleni ^b   Papadimitriou, Elli ^a   Grigoropoulos, Petros ^c   Nonni, Aphroditi ^d   Zografos, George ^e   Kyriakidis, Dimitrios A ^a   Gounaris, Antonia ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Anticancer Institute   (Greece)

^c General Oncological Hospital of Kifissia Agioi Anargiroi   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Breast cancer; Heterozygosity; Mutations; Phosphorylation; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; DNA; MICROSATELLITE DNA; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST LESION; CANCER PATIENT; CLINICAL ARTICLE; EXON; FEMALE; GENE LOCUS; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATOR GENE; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME TEN GENE; PROTEIN EXPRESSION; SYSTEMIC CIRCULATION; TUMOR SUPPRESSOR GENE; BREAST; BREAST TUMOR; CASE CONTROL STUDY; CHROMOSOME 10; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; HETEROZYGOSITY LOSS; IMMUNOBLOTTING; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; METABOLISM; MUTATION; MUTATIONS; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PTEN; SINGLE STRAND CONFORMATION POLYMORPHISM;

BREAST CANCER; HETEROZYGOSITY; MUTATIONS; PHOSPHORYLATION; PTEN;

BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 10; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MUTATION; PHOSPHORYLATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899684884     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
2. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
3. Li DM and Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124-2129, 1997.
4. Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 264: 19-41, 2001.
5. Yamada KM and Araki M: Tumor suppressor PTEN: modulator of cell signalling, growth, migration and apoptosis. J Cell Sci 114: 2375-2382, 2001.
6. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004.
7. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
8. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
9. Engelman J, Luo J and Cantley L: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006.
10. Hlobilkováa A, Knillováa J, Bartekb J, Lukašb J and Kolařa Z: The mechanism of action of the tumour suppressor gene pten. Biomed 147: 19-25, 2003.
11. Planchon SM, Waite KA and Charis E: The nuclear affairs of PTEN. J Cell Biol 121: 249-253, 2008.
12. Leslie N, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, Lim J, Maccario H and Downes C: Indirect mechanisms of carcinogenesis via down-regulation of PTEN function. Adv 50: 112-118, 2010.
13. Okahara F, Ikawa H, Kanaho Y and Maehama T: Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 279: 45300-45303, 2004.
14. Shetty PJ, Pasupuleti N, Chava S, Nasaruddin K and Hasan Q: Altered transcription and expression of PTEN in breast tumors: Is it regulated by hypermethylation? Breast Dis 33: 27-33, 2011.
15. Singh B, Ittmann MM and Krolewski JJ: Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166-171, 1998.
16. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P and Bonilla F: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237-243, 1999.
17. Azim H and Azim HA Jr: Targeting Her-2/neu in Breast Cancer: As Easy as This! Oncology 74: 150-157, 2008.
18. Pandolfi PP: Breast cancer - Loss of PTEN predicts resistance to treatment. N Engl J Med 351: 2337-2338, 2004.
19. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN and Yu D: PTEN, PIK3CA, p-AKT, and p-p70S6K Status. Association with Trastuzumab Response and Survival in Patients with HER2- Positive Metastatic Breast Cancer. Am J Pathol 177: 1647-1656, 2010.
20. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK and Chang JC: Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers. J Clin Oncol 29: 166-173, 2011.
21. Van't Veer LJ, Dai H, Vijver MJ, van de, He YD, Hart AA, Mao M, Peterse HL, Kooy K, van der, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
22. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D and Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
23. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Mania BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
24. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y and Shimizu N: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer Res Clin Oncol 94: 247-252, 2006.
25. Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millasseau P, Marc S, Benardi G, Lathrop M and Weissenbach J: The 1993-94 Genethon human genetic linkage map. Nature Genet 7: 246-339, 1994.
26. Moschonas NK, Spurr NK and Mao J: Report of the first international workshop on human chromosome 10 mapping 1995. Cytogenet Cell Genet 72: 99-112, 1996.
27. Nelen MR, Padberg GW, Peeters EAJ, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MMM, Easton DF, Eeles RA, Hodgson S, Mulvihill JJ, Murday VA, Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Ropers HH, Kremer H, Longy M and Eng C: Localization of the gene for Cowden disease to chromosome 10q22-23. Nature Genet 13: 114-116, 1996.
28. Goudet J: FSTAT, a program to estimate and test gene diversities and fixation indices (version 2.9.3), 2001.
29. Nei M: Molecular Evolutionary Genetics. Columbia University Press, New York, 1987.
30. Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15: 532-537, 1993.
31. Bradford MM: Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Chem 72: 248-254, 1976.
32. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
33. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 76: 4350-4354, 1979.
34. Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T and Dai F: PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 136: 1303-1311, 2010.
35. Rahdara M, Inouea T, Meyerc T, Zhangb J, Vazquezd F and Devreotesa PN: A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. PNAS 106: 480-485, 2009.
36. Okamura Y and Dixon JE: Voltage-Sensing Phosphatase: Its Molecular Relationship With PTEN. Physiology 26: 6-13, 2011.
37. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi S-J, Kim H-J, Misteli T, Jiang X and Pandolfi PP: Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression. Cell 128: 141-156, 2007.
38. Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998.
39. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A and Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559, 2005.
40. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y and Maehara Y: Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 101: 249-257, 2007.
41. Dillon RL, White DE and Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26: 1338-1345, 2007.
42. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, Vijver MJ, van de Valero V, Gray JW, Bernards R, Mills GB and Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091, 2008.
43. Bose S, Wang SI, Terry MB, Hibshoosh H and Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123-127, 1998.
44. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WCW, Eng C, Mulligan LM and Longy M: Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718-723, 1999.
45. McWhinney SR and McLeod HL: Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10: 489-493, 2009.
46. Xie B, Freudenheim JL, Cummings SS, Singh B, He H, McCann SE, Moysich KB and Shields PG: Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis 27: 307-310, 2006.
47. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA and Stout M: Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111: 157-163, 2007.
48. Zhang XC, Piccini A, Myers MP, Van Aelst L and Tonks NK: Functional analysis of the protein phosphatase activity of PTEN. Biochem J 444: 457-464, 2012.
49. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C and von Deimling A: PTEN mutation in gliomas and glioneuronal tumors. Oncogene 16: 2259-2264, 1998.
50. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, Iliev D, Vinson VL, Tavtigian SV and Perry WL: Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 12: 905-910, 1998.
51. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz Jr. LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
52. Cancer Genome Atlas Research Network; Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
53. Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ and Pollock PM: Inhibition of activated fibroblast growth factor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68: 6902-6907, 2008.
54. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ and Bell DW: A unique spectrum of somatic PIK3CA (p110a) mutations within primary endometrial carcinomas. Clin Cancer Res 17: 1331-1340, 2011.
55. Bussaglia E, del Río E, Matías-Guiu X and Prat J: PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31: 312-317, 2000.
56. Orbo A, Kaino T, Arnes M, Kopp M and Eklo K: Genetic derangement in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Gynecol Oncol 95: 82-88, 2004.
57. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C and Segalov E: PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23: 617-28, 2004.
58. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu Z-Z, Molloy PL, Whitehall VL, Leggett BA, Jones IT, Denning G, Jean-Joseph B, Prince C, Durden DL and Vogt PK: A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene 26: 3930-3940, 2007.
59. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL and Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253-1260, 1999.
60. López-Knowles E, O'Toole SA, McNeil CM, Millar EKA, Qiu MR, Crea P, Daly RJ, Musgrove EA and Sutherland RL: PI3K pathway activation in breast cancer is associated with the basallike phenotype and cancer-specific mortality. Int J Cancer 126: 1121-1131, 2009.
61. Huang GL, Zhang ZH, Guo GL, Huang KT, Yang KY, Shen X, You J and Hu ZQ: Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 21: 673-679, 2009.
62. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos AM and Nakopoulou L: Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive carcinomas. Histopathology 56: 876-882, 2010.
63. Qi L, Bart J, Tan LP, Platteel I, van der Sluis T, Huitema S, Harms G, Fu L, Hollema H and van den Berg A: Expression of miR-21 and its targets (PTEN, PDCD4, TMI) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and unvasive carcinoma. BMC Cancer 9: 163-170, 2009.
64. Leslie NR and Downes CP: PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382: 1-11, 2004.
65. Vazquez F, Ramaswamy S, Nakamura N and Sellers WR: Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018, 2000.